Terns Pharmaceuticals(TERN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in September 2024 Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemia (CML) expected in December 2024 Cash, cash equivalents and marketable securities of $225 million, expected to provide runway into 2026 FOSTER CITY, Calif., August 5, 2 ...